Thrivent Financial for Lutherans Decreases Position in CVS Health Corporation $CVS

Thrivent Financial for Lutherans lessened its holdings in CVS Health Corporation (NYSE:CVS) by 9.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 94,768 shares of the pharmacy operator’s stock after selling 10,316 shares during the period. Thrivent Financial for Lutherans’ holdings in CVS Health were worth $7,525,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CVS. Sei Investments Co. boosted its position in CVS Health by 17.4% in the 2nd quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock valued at $62,474,000 after buying an additional 134,535 shares during the period. The Manufacturers Life Insurance Company boosted its position in CVS Health by 1.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock valued at $77,353,000 after buying an additional 13,329 shares during the period. Treasurer of the State of North Carolina boosted its position in CVS Health by 1.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock valued at $40,358,000 after buying an additional 7,588 shares during the period. HUB Investment Partners LLC boosted its position in CVS Health by 25.0% in the 2nd quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock valued at $1,039,000 after buying an additional 3,011 shares during the period. Finally, Alliancebernstein L.P. boosted its position in CVS Health by 8.0% in the 2nd quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock valued at $111,017,000 after buying an additional 119,439 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS highlighted new community and workforce initiatives, including support for military families, a mobile food and chronic-care program in Louisiana, and an online pre-pharmacy degree program with WGU, all of which reinforce its health-care and talent pipeline strategy. CVS Health Reinforces Longstanding Support for the Military Community
• Positive Sentiment: Investors are also focused on bullish commentary about CVS as a “trending stock” and a potential rally that could continue, which may be reinforcing momentum in the shares. CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
• Positive Sentiment: CVS-related coverage continued to emphasize its health-care reach and dividend appeal, helping support investor interest in the name. CVS Health Stock Is Soaring. Could the Rally Just Be Getting Started?
• Neutral Sentiment: A CVS study found many Medicare members lack digital health literacy, which underscores a consumer-service challenge but does not appear to be a direct financial catalyst. Medicare members lack digital health literacy: CVS study
• Negative Sentiment: More importantly, University of Michigan hospitals alleged CVS diverted $66 million in a “secret pricing scheme,” which could raise legal, reputational, and regulatory overhang for CVS Health. CVS diverted $66M in ‘secret pricing scheme,’ University of Michigan hospitals allege

Insider Buying and Selling

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.85% of the stock is owned by corporate insiders.

CVS Health Price Performance

CVS Health stock opened at $93.45 on Thursday. The stock has a market cap of $119.24 billion, a P/E ratio of 41.17, a price-to-earnings-growth ratio of 0.92 and a beta of 0.60. The company has a fifty day simple moving average of $79.69 and a 200-day simple moving average of $78.87. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $98.43. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities analysts expect that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CVS. Argus raised their price target on shares of CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. Bank of America decreased their price target on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research report on Tuesday, January 27th. Wolfe Research decreased their price objective on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research report on Monday, March 2nd. Truist Financial lifted their price objective on shares of CVS Health from $98.00 to $102.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, CVS Health currently has a consensus rating of “Moderate Buy” and an average target price of $98.68.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.